Diflunisal Offlabel denied as duplicate or overlapping therapy by Humana?
If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.
US health-plan appeal rights
Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules
Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.
What Humana typically requires
Humana's specific coverage criteria for diflunisal offlabel are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.
The Humana angle on Diflunisal Offlabel
## Why Humana Denied Diflunisal (Off-Label Use) as Duplicate Therapy
Diflunisal is an NSAID approved for pain and inflammation, but it has an established off-label use in the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) and hereditary transthyretin amyloidosis (hATTR) as a transthyretin stabilizer. A "duplicate therapy" denial in this context typically means Humana's pharmacy or utilization review system flagged that the patient is already receiving another agent classified in the same therapeutic category — most often a newer, on-label transthyretin stabilizer (such as tafamidis) or another NSAID for a concurrent indication. The duplicate-therapy rule is designed to prevent simultaneous prescribing of drugs with the same mechanism when only one is needed, but it can misfire when the two agents are being used for different indications or when the patient tried the comparator agent and it was inadequate.
## Why This Denial Is Appealable
If diflunisal is being used off-label for ATTR amyloidosis and the comparator is either (a) a different class of agent, (b) being used for a separate indication, or (c) a drug the patient previously failed or cannot tolerate, the duplicate-therapy classification is clinically incorrect. Your prescriber can document the specific clinical rationale distinguishing the two agents.
## Federal Appeal Framework
Under ACA Section 2719 and ERISA Section 503, this adverse benefit determination is subject to mandatory internal appeal and, if upheld, independent external review. File the internal appeal within the deadline on the denial notice (commonly 180 days). After a final internal denial, you have generally four months to request independent external review. Expedited review is available for urgent situations.
## Documentation to Gather
- Prescription records for both agents: Dates initiated, indication for each, and prescribing physician.
- Clinical distinction letter: A letter from the prescribing physician explaining why the two agents are not duplicative — e.g., different mechanism, different indication, or diflunisal added after failure of or intolerance to the comparator.
- Diagnosis confirmation: Records establishing the ATTR amyloidosis diagnosis (genetic testing results, cardiac imaging, biopsy if performed) and any concurrent indication for the other agent.
- Applicable guideline reference: Generic citation to the relevant professional society guidance (e.g., the applicable AHA/ACC heart failure guideline or amyloidosis expert consensus) supporting combined or sequential use where clinically indicated.
## Criteria-Mapping Structure
| Humana Duplicate-Therapy Rule | Patient-Specific Counter-Evidence | |---|---| | [Copy Humana's duplicate-therapy criterion verbatim] | [How the two agents differ in indication, mechanism, or clinical history for this patient] |
Next steps
- Find the date on the denial letter — your appeal window starts there.
- Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
- Request the insurer's claim file in writing — they must provide it.
- Submit your appeal in writing with new clinical evidence and a physician statement.
Get the letter drafted
DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.
Start my appeal — $30 with code SEO25 →